Samples test

The next generation of biopsy instruments

27 Apr 2021

Read the full report here:

Initial_Coverage_Neodynamics_2021_04_27


NeoDynamics is a MedTech company that has developed a new generation of breast biopsy instruments. Commercial introduction is underway. Clinical trials are used as traction. Read our investment case (pp. 3-8) and valuation (pp. 32-36) for a shorter overview of the case.

New generation of breast biopsy instruments

NeoDynamics has invented NeoNavia, which is a powered biopsy instrument with three disposable needles that easily cuts through tissue and positions the needle in the correct location with no risk of overshooting the target. Its micro pulse technology is patented. The new proprietary needle type FlexiPulse gives 300 percent larger specimens in a tissue model. It is being evaluated in axillary (armpit) biopsy. Axillae are a sensitive part of the body, full of blood vessels and nerves, for which traditional biopsy instruments are not suited.

The product development is complete and NeoNavia has a CE certification. Commercialization is underway, with the first order having been received during the fourth quarter of 2020. The company is well prepared for the commercialization. Large sums are invested in two clinical trials with around 500 patients between them. The important FDA 510(k) application (for the US market) has been delayed but should be submitted by mid-year 2021. The company’s largest shareholder, who is a Chinese company, will be responsible for clearance and sales in China.

Investment thesis

In our opinion, the investment thesis for NeoDynamics boils down to the company succeeding on the American market. Clinical trials and sales to clinics in Europe will initially be important as testing grounds and for user references. We expect a clinical trial on the US market starting in 2022 together with a simultaneous market introduction. If successful, this could lead to a partnership with a large American company around 2023. This partner should be able to expand US sales quickly, which should lead to NeoDynamics becoming cash flow positive. Over time, the European and Chinese market should gradually catch up with the US market and contribute with growing positive cash flows. A sale of NeoDynamics to a larger MedTech company is likely if commercialization is successful in the USA.

Valuation

We believe that the share is weighed down by the latest directed share issue of about SEK 90m from November last year. We value the company at SEK 5.55 in the base case scenario. Our bear scenario valuation is SEK 2.90, while our bull scenario valuation is SEK 7.76. Compared to a group of similar Swedish MedTech companies, NeoDynamics has a low market cap and enterprise value despite being in a more advanced stage.

Disclaimer

Carlsquare AB, www.carlsquare.se, hereinafter referred to as Carlsquare, conducts business with regard to Corporate Finance and Equity Research in which areas it, among other things, publishes information about companies including analyzes. The information has been compiled from sources that Carlsquare considers to be reliable. However, Carlsquare cannot guarantee the accuracy of the information. Nothing written in the analysis should be regarded as a recommendation or invitation to invest in any financial instrument, option or the like. Opinions and conclusions expressed in the analysis are intended only for the recipient.

The content may not be copied, reproduced or distributed to another person without the written approval of Carlsquare. Carlsquare shall not be held responsible for any direct or indirect damage caused by decisions made on the basis of information contained in this analysis. Investments in financial instruments provide opportunities for value increases and profits. All such investments are also subject to risks. Risks vary between different types of financial instruments and combinations of these. Historical returns should not be considered as an indication of future returns.

The analysis is not directed to U.S. persons (as defined in Regulation S of the United States Securities Act and interpreted in the United States Investment Company Act 1940) nor may it be disseminated to such persons. The analysis is also not directed to such natural and legal persons where the distribution of the analysis to such persons would result in or entail a risk of a violation of Swedish or foreign law or constitution.

The analysis is a so-called Commissioned Research Report where the analyzed Company has signed an agreement with Carlsquare for analysis coverage. The analyzes are published on an ongoing basis during the contract period and for a usual fixed remuneration.

Carlsquare may or may not have a financial interest in the subject of this analysis. Carlsquare values the assurance of objectivity and independence and has established procedures for managing conflicts of interest for this purpose.

The analyst Richard Ramanius does not own and is not allowed to own shares in the company analyzed.

Team

Picture of Jessica Algner
Jessica Algner

Assistant

Telephone: +49 30 809 33 47-12

LinkedIn

@

Picture of Polina Amini
Polina Amini

Senior Associate

Telephone: +49 40 300 836-14

LinkedIn

@

Picture of Markus Augustsson
Markus Augustsson

Head of Equity Research

Telephone: +46 76 235 03 20

LinkedIn

@

Picture of Agata Barsallo
Agata Barsallo

Office Management & Accounting

Telephone: +44 20 8017 6020

@

Picture of Caroline Berglund
Caroline Berglund

Head of Equity Sales

Telephone: +46 73 382 10 82

LinkedIn

@

Picture of Anders Bo
Anders Bo

Managing Partner

Telephone: +45 4199 8252

LinkedIn

@

Picture of Ulf Boberg
Ulf Boberg

Senior Advisor Life Sciences

Telephone: +46 73 312 44 90

LinkedIn

@

Picture of Manfred Drax
Manfred Drax

Partner

Telephone: +49 89 255 49 53-15

LinkedIn

@

Picture of Germar Ebner
Germar Ebner

Associate

Telephone: +49 40 300 836-26

LinkedIn

@

Picture of Anders Elgemyr
Anders Elgemyr

Managing Partner

Telephone: +46 70 496 18 15

LinkedIn

@

Picture of Maximilian Fidel
Maximilian Fidel

Associate

Telephone: +49 89 255 49 53 24

@

Picture of Sebastian Fischer
Sebastian Fischer

Director

Telephone: +49 89 255 49 53-12

LinkedIn

@

Picture of Daniel Garlipp
Daniel Garlipp

Managing Partner

Telephone: +49 40 300 836-19

LinkedIn

@

Picture of Philip Goldhahn
Philip Goldhahn

Vice President

Telephone: +49 40 300 836-21

LinkedIn

@

Picture of Thorsten Grandt
Thorsten Grandt

Vice President

Telephone: +49 30 809 33 47-20

LinkedIn

@

Picture of Johan Heigard
Johan Heigard

Vice President

Telephone: +46 70 246 99 88

LinkedIn

@

Picture of Caroline Heintz
Caroline Heintz

Associate

Telephone: +46 707 40 68 58

@

Picture of Maurice Hinrichs
Maurice Hinrichs

Associate

Telephone: +49 40 300 836-20

LinkedIn

@

Picture of Arnold Holle
Arnold Holle

Managing Partner

Telephone: +44 20 80176020

LinkedIn

@

Picture of Lars Johansen
Lars Johansen

IT&Telecom Expert

@

Picture of Elaine Kelly
Elaine Kelly

Head of Marketing

Telephone: +49 40 300 836 18

LinkedIn

@

Picture of Anna-Lena Kickbusch
Anna-Lena Kickbusch

Office Management & Accounting

Telephone: +49 40 300 836 10

LinkedIn

@

Picture of Morten Kjærulff
Morten Kjærulff

Partner

Telephone: +45 2634 9031

LinkedIn

@

Picture of Mischa Krause
Mischa Krause

Director

Telephone: +49 40 300 836-24

LinkedIn

@

Picture of Steffen Leckert
Steffen Leckert

Managing Partner

Telephone: +49 89 255 49 53 26

LinkedIn

@

Picture of Malve Liebig
Malve Liebig

Senior Associate

Telephone: +49 89 255 49 53-18

LinkedIn

@

Picture of Erik Lundberg
Erik Lundberg

Director

Telephone: +46 73 850 35 59

LinkedIn

@

Picture of Eva Macha
Eva Macha

Office Management & PA to Michael Moritz

Telephone: +49 30 809 33 47-10

LinkedIn

@

Picture of Mandy May
Mandy May

Head of Operations

Telephone: +49 30 809 33 47 16

LinkedIn

@

Picture of Mirja Meyer
Mirja Meyer

Office Management & Accounting

Telephone: +49 40 300 836 10

@

Picture of Mark Miller
Mark Miller

Managing Partner

Telephone: +49 40 300 836-11

LinkedInXING

@

Picture of Michael Moritz
Michael Moritz

Managing Partner

Telephone: +49 30 809 33 47-13

LinkedIn

@

Picture of Bertil Nilsson
Bertil Nilsson

Senior Equity Analyst

Telephone: +46 70 434 90 03

LinkedIn

@

Picture of Flemming C. Pedersen
Flemming C. Pedersen

Managing Partner

Telephone: +45 4199 8251

LinkedIn

@

Picture of Richard Ramanius
Richard Ramanius

Associate Equity Analyst

Telephone: +46 73 539 66 99

LinkedIn

@

Picture of Anika Schaefer
Anika Schaefer

Office Management & HR

Telephone: +49 89 255 495 310

@

Picture of Alexander Schleppegrel
Alexander Schleppegrel

Associate

Telephone: +45 2621 0543

LinkedIn

@

Picture of Nico Schmidt-Weidemann
Nico Schmidt-Weidemann

Partner

Telephone: +49 89 255 49 53-17

@

Picture of Caspar Graf Stauffenberg
Caspar Graf Stauffenberg

Managing Partner

Telephone: +49 89 255 49 53-11

LinkedIn

@

Picture of Gregor Steins
Gregor Steins

Associate

Telephone: +49 40 300 836-15

LinkedIn

@

Picture of Jon Tingling
Jon Tingling

Associate

Telephone: +44 77 1347-8286

LinkedIn

@

Picture of Sybille de Vegvar
Sybille de Vegvar

Business Development & Marketing

Telephone: +44 20 8017 6017

@

Picture of Oskar Wollert
Oskar Wollert

Vice President

Telephone: +46 761 71 11 60

@

Picture of Nils Zettelmeyer
Nils Zettelmeyer

Director

Telephone: +49 30 809 33 47-25

LinkedIn

@

Picture of Andreas Zetzsche
Andreas Zetzsche

Partner

Telephone: +49 30 809 3347 33

@

Picture of Gerrit Zwarg
Gerrit Zwarg

Senior Associate

Telephone: +49 40 300 836-28

LinkedIn

@